STATegics, Inc. Announces Issuance of a Second Patent by the U.S. Patent and Trademark Office for Small Molecule Thrombopoietin Mimetics MENLO PARK, Calif., March 27, 2012 (GLOBE NEWSWIRE) -- STATegics, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has issued a second patent for its small molecule...

STATegics, Inc. Announces a Grant From Friedreich's Ataxia Research Alliance to Support Its Program to Develop Small Molecule Mimetics of Erythropoietin for the Treatment of Friedreich's Ataxia MENLO PARK, Calif., Aug. 2, 2011 (GLOBE NEWSWIRE) -- STATegics, Inc. announced today that the Friedreich's Ataxia Research Alliance (FARA) has awarded the Company $152,690 to advance its proprietary...

STATegics, Inc. Announces Award from the Department of Defense to Advance Proprietary Small Molecule Mimetics of Erythropoietin for the Treatment of Traumatic Brain Injury SUNNYVALE, Calif., Nov. 16, 2010 (GLOBE NEWSWIRE) -- STATegics, Inc. announced today that the Department of Defense has awarded the Company $1.7 million to advance its proprietary small molecule...

STATegics, Inc. Announces Patent Issued by the U.S. Patent and Trademark Office for Small Molecule Thrombopoietin Mimetics SUNNYVALE, Calif., Aug. 31, 2010 (GLOBE NEWSWIRE) -- STATegics, Inc., a biopharmaceutical company committed to the discovery and development of orally available small molecule modulators of cytokine...